Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the quick ratio (acid-test) high or low?
The quick ratio (acid-test) of 4.07 is 59% below its 5-year average of 10.03, near the low end of its 5-year range (1.99–23.48).
As of the fiscal period ended Tuesday, June 30, 2026. 35.93% above its 12-month average of 3.00.
Reported quarterly quick ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 4.07.
QUICK RATIO (ACID-TEST)
4.07
QUICK RATIO (ACID-TEST) AVG TTM
3.00
QUICK RATIO (ACID-TEST) AVG 3Y
7.21
QUICK RATIO (ACID-TEST) AVG 5Y
10.03
QUICK RATIO (ACID-TEST) AVG 10Y
N/A
QUICK RATIO (ACID-TEST) AVG 15Y
N/A
QUICK RATIO (ACID-TEST) AVG 20Y
N/A
CURRENT VS TTM AVG
+35.93%
CURRENT VS 3Y AVG
-43.56%
CURRENT VS 5Y AVG
-59.40%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.28
median of 794 covered companies
CURRENT VS SECTOR MEDIAN
+24.14%
vs the sector median at left
Prelude Therapeutics Incorporated
Market Cap
$213.21M
Quick Ratio (Acid-Test)
4.07
TTM Avg
3.00
3Y Avg
7.21
5Y Avg
10.03
Market Cap
$213.44M
Quick Ratio (Acid-Test)
5.13
TTM Avg
3.45
3Y Avg
2.59
5Y Avg
2.27
Market Cap
$211.48M
Quick Ratio (Acid-Test)
5.26
TTM Avg
3.62
3Y Avg
4.54
5Y Avg
4.95
Market Cap
$211.33M
Quick Ratio (Acid-Test)
5.72
TTM Avg
5.91
3Y Avg
5.85
5Y Avg
7.15
Market Cap
$216.34M
Quick Ratio (Acid-Test)
344.31
TTM Avg
177.51
3Y Avg
95.13
5Y Avg
76.52
Market Cap
$208.32M
Quick Ratio (Acid-Test)
20.05
TTM Avg
17.55
3Y Avg
12.54
5Y Avg
12.54
Market Cap
$207.98M
Quick Ratio (Acid-Test)
7.48
TTM Avg
9.04
3Y Avg
6.33
5Y Avg
4.86
Market Cap
$206.06M
Quick Ratio (Acid-Test)
2.45
TTM Avg
2.08
3Y Avg
1.84
5Y Avg
1.77
Market Cap
$206.61M
Quick Ratio (Acid-Test)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | QUICK RATIO (ACID-TEST) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $213.21M | 4.07 | 3.00 | 7.21 | 10.03 |
| Niagen Bioscience Inc (NAGE)vs › | $213.44M | 5.13 | 3.45 | 2.59 | 2.27 |
| Alector, Inc. (ALEC)vs › | $211.48M | 5.26 | 3.62 | 4.54 | 4.95 |
| Compugen Ltd. (CGEN)vs › | $211.33M | 5.72 | 5.91 | 5.85 | 7.15 |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.34M | 344.31 | 177.51 | 95.13 | 76.52 |
| Sionna Therapeutics, Inc. (SION)vs › | $208.32M | 20.05 | 17.55 | 12.54 | 12.54 |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $207.98M | 7.48 | 9.04 | 6.33 | 4.86 |
| Pro-Dex, Inc. (PDEX)vs › | $206.06M | 2.45 | 2.08 | 1.84 | 1.77 |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $220.74M | 5.36 | 6.17 | 11.50 | 11.99 |
Quick Ratio
4.07
Excludes inventory
Current Ratio
4.07
Includes inventory
Quick Ratio = (Current Assets − Inventory) / Current Liabilities
The quick ratio is a stricter liquidity measure that excludes inventory, showing the ability to meet short-term obligations with the most liquid assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | QUICK RATIO (ACID-TEST) |
|---|---|
| 2026-06-30 | 4.07 |
| 2026-03-31 | 2.03 |
| 2025-12-31 | 1.99 |
| 2025-09-30 | 3.21 |
| 2025-06-30 | 3.68 |
| 2025-03-31 | 5.18 |
| 2024-12-31 | 5.30 |
| 2024-09-30 | 7.04 |
| 2024-06-30 | 7.83 |
| 2024-03-31 | 11.64 |
| 2023-12-31 | 10.79 |
| 2023-09-30 | 13.91 |
| 2023-06-30 | 17.13 |
| 2023-03-31 | 8.91 |
| 2022-12-31 | 9.42 |
| 2022-09-30 | 10.52 |
| 2022-06-30 | 15.72 |
| 2022-03-31 | 16.80 |
| 2021-12-31 | 15.37 |
| 2021-09-30 | 16.57 |
| 2021-06-30 | 23.48 |
| 2021-03-31 | 29.38 |
| 2020-12-31 | 19.41 |
| 2020-09-30 | 20.96 |
| 2020-06-30 | 5.44 |
| 2020-03-31 | 0.00 |
| 2019-12-31 | 4.18 |
| 2019-09-30 | 0.00 |
| 2019-06-30 | 0.00 |
| 2019-03-31 | 0.00 |
